**Question:** Which one of the statements is false regarding adefovir dipivoxil?

A. Adefovir dipivoxil is a prodrug that is converted into its active form, adefovir, by cellular enzymes.
B. Adefovir dipivoxil is commonly used for the treatment of chronic hepatitis B virus (HBV) infection.
C. Adefovir dipivoxil is a nucleoside reverse transcriptase inhibitor (NRTI).
D. Adefovir dipivoxil is selectively transported into the liver cells by specific transporters.

**Core Concept**
Adefovir dipivoxil is an antiviral medication primarily used in the treatment of chronic hepatitis B virus (HBV) infection. It is a prodrug that is converted into its active form, adefovir, within the target cell by cellular enzymes. Adefovir dipivoxil belongs to the class of antiviral drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

**Why the Correct Answer is Right:**
Adefovir dipivoxil is selectively transported into the liver cells by specific transporters, allowing it to reach high concentrations in the site of action (hepatic cells infected by HBV), and subsequently inhibit viral replication. The medication is a potent inhibitor of HBV DNA polymerase, leading to suppression of HBV replication and reduction in viral load. This helps in managing the disease progression and liver damage associated with chronic HBV infection.

**Why Each Wrong Option is Incorrect:**

A. False: Adefovir dipivoxil is transported into liver cells, not specifically into the infected cells. It is not selective for HBV-infected cells, making this statement inaccurate.

B. False: Adefovir dipivoxil is primarily used for the treatment of chronic hepatitis C virus (HCV) infection, not chronic HBV infection. It is specifically designed for the management of HBV, not HCV.

C. False: Adefovir dipivoxil is classified as a nucleoside reverse transcriptase inhibitor (NRTI), not a nucleoside reverse transcriptase inhibitor (NRTI). The correct term is NRTI, not NRTI.

D. False: Adefovir dipivoxil is transported into liver cells, but not specifically into the HBV-infected cells. It is not selective for HBV-infected cells, making this statement inaccurate.

**Clinical Pearl:**
Adefovir dipivoxil is a valuable medication for the management of chronic hepatitis B virus (HBV) infection. Its selective transport into liver cells allows it to target and inhibit the viral replication in hepatocytes, thus reducing the viral load and preventing liver damage. Adefovir dipivoxil belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), not nucleoside reverse transcriptase inhibitors (NRTIs).